| Name | Title | Contact Details |
|---|---|---|
Jessica Castro |
Associate Director, Benefits | Profile |
Maria Fico |
Director, Human Resources Business Partner | Profile |
Bill VanNewkirk |
Director, Talent Acquisition Seqirus/CO/RandD/Americas | Profile |
James Peterson |
Director R&D Project Management | Profile |
Greg Healy |
Sr. Director, Head of Global R&D Communications | Profile |
NextPhase Medical Device — Medical Device Contract Manufacturing Company–Your single source contract manufacturing company for medical device design, development, manufacturing, assembly, and complete supply chain management. We specialize in Sterile S...
Help control your eye pressure and possibly reduce your need for Glaucoma medication with the Hydrus® Microstent.
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Therapy designed to address an unmet and growing need in the CNS and substance abuse space.